MacroGenics Inc. (MGNX)

Business: MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.

IPO Date: 10-Oct-2013

Pres, CEO & Director: Dr. Scott Koenig M.D., Ph.D.

Sr. VP, CFO & Corp. Sec.: Mr. James Karrels

Listing: NASDAQ: MGNX

Country: United States

Headquarters: Rockville, MD

Website: https://www.macrogenics.com

Market cap: $187.07 Mln

Revenue (TTM): $70.25 Mln

Earnings (TTM): $-217.29 Mln

Cash: $183.99 Mln

Total Debt: $24.35 Mln

Insider's Holding: 2.60%

Liquidity: Low

52 Week range: $2.13 - 29.16

Shares outstanding: 61,333,500

10 Years Aggregate:

• CFO: $-639.68 Mln
• EBITDA: $-720.70 Mln
• Net Profit: $-783.62 Mln